The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products.
Glaucoma
‘PharmaPoint: Glaucoma’ predicts that five products, currently in late-stage pipeline, will enter the market during the forecast period. These five products include Santen’s drug DE-117m Aerie’s fixed-dose combination therapy (Roclatan), two sustained-release implants and a drug with an undisclosed MOA.